This study analyzed insurance claims data from before and after the implementation of the Federal Mental Health Parity and Addiction Equity Act to examine the effects of parity on substance use disorder treatment. The results showed:
1) There was no change in the use of substance use disorder services or the total annual spending per enrollee on these services (which increased by only $10 per enrollee).
2) There was also no change in out-of-pocket spending for substance use disorder treatment users or several HEDIS quality measures related to identification and initiation of treatment.
3) This suggests that concerns about parity greatly increasing health care costs related to substance use disorder treatment were unfounded.
Pharmacovigilance presentation Workshop - Adam Kwan, B.Sc, Amjad Atrash, B.Sc Pharmacy, Lia Alderete, B.Sc MLT Valentyna Burbelo, M.Sc. Pharmaceutical Sciences, Professor Peivand Pirouzi
Do House Officers Learn from their Mistakes?
Pharmacovigilance presentation Workshop - Adam Kwan, B.Sc, Amjad Atrash, B.Sc Pharmacy, Lia Alderete, B.Sc MLT Valentyna Burbelo, M.Sc. Pharmaceutical Sciences, Professor Peivand Pirouzi
Do House Officers Learn from their Mistakes?
Team Lift: Predicting Medication AdherenceNeil Ryan
Medication adherence is a growing public health concern in the US. It is the extent to which patients are taking medications as prescribed by their healthcare providers. Simply put, are patients eating their pills on time?
We looked at patient data from Medicare part D program released by Centers for Medicare & Medicaid services. We built a prediction model to ascertain whether a patient would be adherent based on a variety of social, economic and behavioral aspects.
Computer Decision Support Systems and Electronic Health Records: Am J Pub Hea...Lorenzo Moja
We systematically reviewed randomized controlled trials (RCTs) assessing the ef- fectiveness of computerized decision support systems (CDSSs) featuring rule- or algorithm-based software integrated with electronic health records (EHRs) and evidence-based knowledge. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Abstracts of Reviews of Effects. Information on system design, capabilities, acquisition, implementation context, and effects on mortality, morbidity, and economic outcomes were extracted.
Twenty-eight RCTs were included. CDSS use did not affect mortality (16 trials, 37395 patients; 2282 deaths; risk ratio [RR] = 0.96; 95% con- fidence interval [CI]=0.85, 1.08; I2 = 41%). A statistically significant effect was evident in the prevention of morbidity, any disease (9 RCTs; 13868 patients; RR = 0.82; 95% CI = 0.68, 0.99; I2 = 64%), but selective outcome reporting or publication bias cannot be excluded. We observed differences for costs and health service utilization, although these were often small in magnitude.
Across clinical settings, new generation CDSSs integrated with EHRs do not affect mortality and might moderately improve morbidity outcomes. (Am J Pub- lic Health. Published online ahead of print October 16, 2014: e1–e11. doi:10.2105/ AJPH.2014.302164)
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
PCOMS and an Acute Care Inpatient Unit: Quality Improvement and Reduced Readm...Barry Duncan
High psychiatric readmission rates continue while evidence suggests that care is not perceived by patients as “patient centered.” Research has focused on aftercare strategies with little attention to the inpatient treatment itself as an intervention to reduce readmission rates. Quality improvement strategies based on patient-centered care may offer an alternative. We evaluated outcomes and readmission rates using a benchmarking methodology with a naturalistic data set from an inpatient psychiatric facility (N 2,247) that used a quality-improvement strategy called systematic patient feedback. A systematic patient feedback system, the Partners for Change Outcome Management System (PCOMS), was used. Overall pre-post effect sizes were d 1.33 and d 1.38 for patients diagnosed with a mood
disorder. These effect sizes were statistically equivalent to RCT benchmarks for feedback and depression.
Readmission rates were 6.1% (30 days), 9.5% (60 days), and 16.4% (180 days), all lower than national benchmarks. We also found that patients who achieved clinically significant treatment outcomes were less likely to be readmitted. We tentatively suggest that a focus on real-time patient outcomes as well as care that is “patient centered” may provide lower readmission rates.
Non-adherence of CML patients - Results of the global survey of the CML Ad...jangeissler
"Non-adherence of CML patients - Results of the global survey of the CML Advocates Network", presented by Giora Sharf, Co-founder, CML Advocates Network and Director, Israeli CML Patients’ Organization, for the International CML Foundations' "Virtual Education Program"
Team Lift: Predicting Medication AdherenceNeil Ryan
Medication adherence is a growing public health concern in the US. It is the extent to which patients are taking medications as prescribed by their healthcare providers. Simply put, are patients eating their pills on time?
We looked at patient data from Medicare part D program released by Centers for Medicare & Medicaid services. We built a prediction model to ascertain whether a patient would be adherent based on a variety of social, economic and behavioral aspects.
Computer Decision Support Systems and Electronic Health Records: Am J Pub Hea...Lorenzo Moja
We systematically reviewed randomized controlled trials (RCTs) assessing the ef- fectiveness of computerized decision support systems (CDSSs) featuring rule- or algorithm-based software integrated with electronic health records (EHRs) and evidence-based knowledge. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Abstracts of Reviews of Effects. Information on system design, capabilities, acquisition, implementation context, and effects on mortality, morbidity, and economic outcomes were extracted.
Twenty-eight RCTs were included. CDSS use did not affect mortality (16 trials, 37395 patients; 2282 deaths; risk ratio [RR] = 0.96; 95% con- fidence interval [CI]=0.85, 1.08; I2 = 41%). A statistically significant effect was evident in the prevention of morbidity, any disease (9 RCTs; 13868 patients; RR = 0.82; 95% CI = 0.68, 0.99; I2 = 64%), but selective outcome reporting or publication bias cannot be excluded. We observed differences for costs and health service utilization, although these were often small in magnitude.
Across clinical settings, new generation CDSSs integrated with EHRs do not affect mortality and might moderately improve morbidity outcomes. (Am J Pub- lic Health. Published online ahead of print October 16, 2014: e1–e11. doi:10.2105/ AJPH.2014.302164)
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
PCOMS and an Acute Care Inpatient Unit: Quality Improvement and Reduced Readm...Barry Duncan
High psychiatric readmission rates continue while evidence suggests that care is not perceived by patients as “patient centered.” Research has focused on aftercare strategies with little attention to the inpatient treatment itself as an intervention to reduce readmission rates. Quality improvement strategies based on patient-centered care may offer an alternative. We evaluated outcomes and readmission rates using a benchmarking methodology with a naturalistic data set from an inpatient psychiatric facility (N 2,247) that used a quality-improvement strategy called systematic patient feedback. A systematic patient feedback system, the Partners for Change Outcome Management System (PCOMS), was used. Overall pre-post effect sizes were d 1.33 and d 1.38 for patients diagnosed with a mood
disorder. These effect sizes were statistically equivalent to RCT benchmarks for feedback and depression.
Readmission rates were 6.1% (30 days), 9.5% (60 days), and 16.4% (180 days), all lower than national benchmarks. We also found that patients who achieved clinically significant treatment outcomes were less likely to be readmitted. We tentatively suggest that a focus on real-time patient outcomes as well as care that is “patient centered” may provide lower readmission rates.
Non-adherence of CML patients - Results of the global survey of the CML Ad...jangeissler
"Non-adherence of CML patients - Results of the global survey of the CML Advocates Network", presented by Giora Sharf, Co-founder, CML Advocates Network and Director, Israeli CML Patients’ Organization, for the International CML Foundations' "Virtual Education Program"
With more and more businesses now trying to tout sustainability messaging, Green is the new “Black.” It seems that every company has a Green message these days but how do you translate that message to saving green.
Most companies want to go Green but do not possess the resources to develop an environmental action plan. To help, BMI+ImageNet has put together this checklist in order to assess a company’s Greenability.
The Holy Grail of Monthly Giving: Finding, Keeping and Loving SustainersCare2Team
*Watch or download the full webinar (with audio and slides) at: http://bit.ly/c2grail
Want to find a new, stable source of income that also works as a loyalty booster to existing donors?
Three words: SUSTAINED GIVING PROGRAM
This webinar covers everything you want -- and need -- to know about monthly giving.
Starting with the basics, Harvey McKinnon, renowned expert on monthly giving, discusses why to have a monthly giving program and what it means for donor loyalty, along with the fundamental elements of all good monthly programs.
Next, Teva Harrison of the Nature Conservancy of Canada -- which has made a strategic decision to invest in a monthly program -- tells what works for her organization while sharing secrets, tips and best practices on how to find, keep and love these valuable donors.
In this webinar you'll learn:
-What metrics to look for in a monthly program (eg. typical conversion rates, retention rates)
-How to invite them, what to say, how often to say it
-When to use direct mail and when to use the phone to convert and upgrade
-Great examples from an organization with years of expertise in cultivating these valuable donors
Presenters:
-Harvey McKinnon (President, Harvey McKinnon Associates)
-Teva Harrison (Manager of Supporter Development, Nature Conservancy of Canada)
-Ryann Miller (Director of Nonprofit Services, Care2)
Research MethodsLaShanda McMahonUniversity o.docxverad6
Research Methods
LaShanda McMahon
University of Phoenix
Formulating the Problem Statement and the Purpose Statement
Over the past decade, there have been several changes in drug addiction treatment that has shown results that show reduced associated health and social costs by more than the cost of the treatments. It has been found that treatments cost much less that the alternatives, such as incarcerating people with addictions. There are many savings related to healthcare, which includes, total savings that can exceed costs with a ratio of 12 to 1. Major savings to the individual and to society also stems from fewer interpersonal conflicts; greater workplace productivity; and fewer drug-related accidents, including overdoses and deaths (Woody, M.D., 2018).
Problem Statement
A common misperception is detoxification cures the addiction, yet addiction is a chronic disorder requiring long term multimodal treatment (Korsmeyer et al., 2009. Long-term treatment for substance abuse and co-occurring disorders might reduce recidivism rates and lessen costs for rehabilitation. Goldstein, A. (1997). examined the benefits of long-term substance abuse and posited the benefits. Goldstein further suggested not treating addiction appropriately or at all contributes to the high costs associated with substance use in the United States.
Insurance companies are reluctant to support long term substance abuse treatment; however, Weisner, Ray, Mertens, Satre and Moore (2003) noted patients receiving a minimum of six months substance treatment abstained from drug and alcohol use at least five years after treatment yet abusers of alcohol were less likely to remain sober for lengthy periods of time after treatment (Weisner et al., 2003).
According to the National Drug Institute (2012), every dollar invested in substance abuse treatment yields a return of $5.50 in reduced drug-related crime, costs associated with criminal justice, and theft. Healthcare savings can exceed costs by a 12 to 1 ratio. Therefore, drug addiction treatment reduces costs associated with primary care and is less costly than incarceration. Addressing addiction also contributes to the more positive aspects of life, such as increase in work productivity, and fewer incidents related to drug use, fewer overdoses and deaths.
Purpose Statement
The purpose of this correlational study is to see if a relationship exists among periods of sobriety and four levels of substance abuse treatment. The research will examine substance abuse treatment throughout various levels of care: higher levels (detox, Inpatient (IP), and Residential (RTC) and lower levels (partial hospitalization (PHP), Intensive Outpatient (IOP), and routine Outpatient (OP). Current trends in substance abuse treatment provides evidence that length of treatment is inadequate contributing to more frequent relapses among substance abusers. Longer treatment options for addiction may reduce the number of relapses, reduce costs asso.
Health co morbidity effects on injury compensation claims in NZ, and evidence...John Wren
This PPT presents the results of a suite of research undertaken to explore the evidence for health comorbidity effects on the cost of injury compensation claims, and what might be done about them. Comorbidity effects were shown to add approximately 10% extra to the cost of claims. There is good evidence that workplace health and wellness programmes are effective if well designed
Dr John Wren
Principal Researcher Advisor
New Zealand Accident Compensation Corporation
PO Box 242, Wellington, New Zealand
john.wren@acc.co.nz
(P23, Thursday 27, Civic Room 3, 1.30)
An Interprofessional Approach to Substance Abuse in Primary CareASAMPUBS
An integrated model of treatment improves care by recognizing that patients need clear and consistent care from their primary care provider “in a way that thoroughly considers biological, social, behavioral, and psychological components of their presenting complaint” by integrating psychological, addiction, and other treatments into a cohesive whole.
The impact of nurse practitioner regulations onpopulation acdaniatrappit
The impact of nurse practitioner regulations on
population access to care
Donna Felber Neff, PhD, RN, FNAPa,*, Sul Hee Yoon, PhDb, Ruth L. Steiner, PhDc,
Ilir Bejleri, PhDb, Michael D. Bumbach, PhD, FNP-BCd, Damian Everhart, PhD, RNe,
Jeffrey S. Harman, PhDf
a College of Nursing, University of Central Florida, Orlando, FL
b Department of Urban and Regional Planning, University of Florida, Gainesville, FL
c Center for Health and the Built Environment, Department of Urban and Regional Planning, University Of Florida, Gainesville, FL
d College of Nursing, Department of Family, Community, and Health System Science, University of Florida, Gainesville, FL
e Centers for Medicare and Medicaid Services, University of Central Florida, Palm City, FL
f Department of Behavioral Sciences & Social Medicine, College of Medicine, Florida State University, Tallahassee, FL
A R T I C L E I N F O
Article history:
Received 15 November 2017
Accepted 5 March 2018
Available online 8 March 2018.
Keywords:
Nurse practitioner scope of
practice
Population access to care
Drive time
State NP practice regulations
A B S T R A C T
Background: By 2025, experts estimate a significant shortage of primary care pro-
viders in the United States, and expansion of the nurse practitioner (NP) workforce
may reduce this burden. However, barriers imposed by state NP regulations could
reduce access to primary care.
Purpose: The objectives of this study were to examine the association between three
levels of NP state practice regulation (independent, minimum restrictive, and most
restrictive) and the proportion of the population with a greater than 30-min travel
time to a primary care provider using geocoding.
Methods: Logistic regression models were conducted to calculate the adjusted odds
of having a greater than 30-min drive time.
Findings: Compared with the most restrictive NP states, states with independent
practice had 19.2% lower odds (p = .001) of a greater than 30-min drive to the closest
primary care provider.
Discussion: Allowing NPs full autonomy to practice may be a relatively simple policy
mechanism for states to improve access to primary care.
Cite this article: Neff, D. F., Yoon, S. H., Steiner, R. L., Bejleri, I., Bumbach, M. D., Everhart, D., & Harman,
J. S. (2018, JULY/AUGUST). The impact of nurse practitioner regulations on population access to care. Nursing
Outlook, 66(4), 379–385. https://doi.org/10.1016/j.outlook.2018.03.001.
Background
The benefits of an adequate supply of primary care pro-
viders on patient health have been well documented in
the scientific literature, including improved care coor-
dination and better overall patient outcomes (Macinko,
Starfield, & Shi, 2007; Starfield, Shi, & Macinko, 2005).
However, a shortage of primary care physicians (MDs)
in the United States is estimated to exceed 52,000 by
2025 (Petterson et al., 2012), most notably in key geo-
graphic locations, including medically underserved and
health professional shortage ...
Running head IMPACT OF SMOKING ON HEALTHCARE COSTS1IMPACT OF.docxcowinhelen
Running head: IMPACT OF SMOKING ON HEALTHCARE COSTS 1
IMPACT OF SMOKING ON HEALTHCARE COSTS 6
Impact of smoking on healthcare costs
Cherod Jones
American Military University
Impact of smoking on healthcare costs
Introduction
In the world today, smoking is one of the things that trigger a significant number of ailments on people. This is the case because tobacco affects almost all internal body organs gradually compromising their functioning (Stewart, & Wild, 2017). The research claims that continued smoking makes a person susceptible to contract more than one ailment, which becomes hard to treat. Many people who smoke have recurring diseases that are hard to get rid of. Smoking negatively affects the cost of healthcare not only because of triggering ailments but in many other aspects. The purpose of this research paper shall focus on the various ways that smoking impacts healthcare cost.
Body of paper
An overview of the issue
Smoking is a complex health challenge that negatively affects the cost of healthcare in different countries around the world, but mainly the U.S. Smoking-related ailments include; stroke, coronary heart disease, cardiovascular disease, damaged and blocked blood vessels, respiratory infections like emphysema, chronic bronchitis, and asthma. Smoking also plays a vital role in the formation and development of all types of cancer. For instance: bladder, blood (acute myeloid leukemia), cervix, esophagus, colon, and rectum (colorectal), kidney and ureter (Lloyd-Jones et al., 2010). According to some researchers, other cancers caused by smoking are; “larynx, liver, oropharynx (includes parts of the throat, tongue, soft palate, and the tonsils), pancreas, stomach, trachea, bronchus, and lung” (Stewart & Wild, 2017). Meaning, that a majority of healthcare issues addressed in different healthcare facilities emanates from smoking. The challenge is that these ailments are complicated and they need high-quality skills, quality medical equipment, and resources to maintain services. Patients will have to incur the high cost of treatment. Therefore smoking causes an escalation in healthcare cost.
Why is this issue a concern from a health care economics perspective?
Ailments emanating from smoking are complex and requires a significant concern for the healthcare economics. The idea is that high skilled medical professionals need to be paid in a manner that is equivalent to the services they are offering. The tools required to diagnose and test are expensive, making healthcare services providing smoking-related ailments treatment costly. Moreover, the medication for such diseases is too strong and goes through a long and tedious process, which makes it hard to cut on the cost of production. In other cases, some of the diseases require surgeries which are complex and sensitive putting a demand on the number of medical surgeons.
Who are the major parties involved in this issue
· Government as they set laws and en ...
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
The Effects of Federal Parity on Substance Use Disorder Treatment_Andrew Epstein 5_7_13
1. The effects of federal parity on substance use disorder treatment
Susan H. Busch, PhD;1 Andrew J. Epstein, PhD;2,3 Michael O. Harhay, MPH;2 David A. Fiellin, MD;1
Hyong Un, MD;4 Deane Leader Jr;4 Colleen L. Barry, PhD MPP5
1 Yale University; 2 University of Pennsylvania; 3 Veterans Affairs; 4 Aetna Inc; 5 Johns Hopkins University
Analyses focused on enrollees in 10 states with
pre-existing SUD parity laws
Under ERISA, fully insured plans are subject to
state parity laws, but self-insured plans are
exempt
Compared pre-post changes in outcomes among
individuals newly subject to federal parity with
changes among individuals already subject to
pre-existing state SUD laws
Used difference-in-differences models
Controlled for enrollee gender, age and state
Logistic regression for binary outcomes
Two-part models for spending outcomes
Method of recycled predictions and
nonparametric block bootstraps to calculate
effect size and confidence intervals
Methods Results
Concern that federal parity would
greatly increase health care spending,
at least related to SUD treatment, was
unfounded
Policy Implications
Historically, more stringent limits on coverage
for mental health and substance use disorder
(SUD) services
In 2008, the U.S. Congress enacted the Paul
Wellstone and Pete Domenici Mental Health
Parity and Addiction Equity Act (MHPAEA)
Required insurers to equalize private
insurance coverage for mental health and SUD
services with coverage for general medical
services
Includes all financial requirements and
treatment limits
Effective January 1, 2010
Expected effects of parity on SUD treatment
are ambiguous, and no published information
is yet available
Background
To examine the effects of the MHPAEA on
substance use disorder treatment
Objectives
Funded by NIH grants
NIDA DA026414 and
NIMH MH093414-01A1
Aetna claims data for members continuously
enrolled during 2009 (pre) and 2010 (post)
Annual total SUD spending per enrollee
includes all SUD-related inpatient, partial
hospitalization, intensive outpatient, and
outpatient services, and Rx drugs
Data and Measures
Baseline characteristics of study sample, 2009
Probability of use & spending per enrollee on
SUD services
Out-of-pocket (OOP) SUD spending per user
HEDIS measures: Identification
HEDIS measures: Treatment initiation
HEDIS measures: Treatment engagement
No change in use of any SUD services
Small increase in total annual SUD cost per
enrollee (i.e., $10 per enrollee per year)
No change in OOP spending per SUD user
No change in HEDIS measures
Summary of findings
Self insured
(N=162,761)
Fully insured
(N=135,578)
(p-value)
N (%) N (%)
Female 84,530 (54.1) 71,755 (52.9) p<0.001
Age p<0.001
18-31 years 40,520 (24.9) 35,205 (26.0)
32-46 years 63,903 (39.3) 50,870 (37.5)
47-62 years 58,338 (35.8) 49,503 (36.5)
Selected diagnoses
• Any substance use disorder
treatment
1,752 (1.1%) 912 (0.7%) p<0.001
• Any alcohol use
disorder treatment
653 (0.4) 342 (0.3) p<0.001
• Any illicit drug use disorder
treatment
1,099 (0.7) 570 (0.4) p<0.001
• Any opioid use
disorder treatment
323 (0.2) 166 (0.1) p<0.001
Change in value before
and after parity
Probability of
using SUD
treatment (%)
Total SUD
spending per
enrollee ($)
Probability
of using SUD
services (%)
Total SUD
spending
per enrollee ($)
Pre
parity
Post
parity
Pre
parity
Post
parity
95% CI 95% CI
Self insured
treatment
group
(N=162,761)
1.04 1.18 36.51 52.62
0.05
[-0.03, 0.12]
9.99
[2.54, 18.21]Fully insured
comparison
group
(N=135,578)
0.70 0.79 26.58 32.70
OOP spending for SUD
services
per user ($)
Change in value
before and after
parity ($)
Pre
parity
Post
parity
95% CI
Self insured
treatment group
449.48 538.70
39.00
[-71.05, 145.13]Fully insured
comparison group
572.23 622.45
Identification of SUD
service receipt (%)
Change in value
before and after
parity (%)
Pre
parity
Post
parity
95% CI
Self insured
treatment group
0.81 0.91
0.01
[-0.074, 0.94]Fully insured
comparison group
0.53 0.62
Treatment initiation (%)
Change in value before
and after parity
Pre
parity
Post
parity
% 95% CI
Self insured
treatment group
34.71 33.33
0.44 [-5.07, 6.40]
Fully insured
comparison group
32.63 30.81
Treatment engagement
(%)
Change in value before
and after parity
Pre
parity
Post
parity
% 95% CI
Self insured
treatment group
19.29 19.57
1.84 [-2.79, 6.65]
Fully insured
comparison group
19.40 17.84